Protection against retinopathy in T2D

Recent research has found that sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower risk for sight-threatening retinopathy than other second-line glucose-lowering medications in patients with Type 2 diabetes.

The five year study – involving 3,544,383 people with newly diagnosed Type 2 diabetes – saw 159,965 of them treated with SGLT2 inhibitors, 304,383 with dipeptidyl peptidase-4 (DPP-4) inhibitors, 108,420 with pioglitazone, and 189,618 with sulfonylurea.

The research found that SGLT2 inhibitors reduced sight-threatening retinopathy risk by 43% vs DPP-4 inhibitors, by 38% vs sulfonylurea, and by 25% vs pioglitazone.

This study was led by Fu-Shun Yen, MD, a private practitioner from Taiwan, and was published on December 20, 2023, in JAMA Network Open.

To find out more, CLICK HERE


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags